Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Vertex Pharmaceuticals's current 3-Year Share Buyback Ratio was 0.40%.
The historical rank and industry rank for Vertex Pharmaceuticals's 3-Year Share Buyback Ratio or its related term are showing as below:
MEX:VRTX'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -20.1 Med: -6.8 Max: 0.4
Current: 0.4
During the past 13 years, Vertex Pharmaceuticals's highest 3-Year Share Buyback Ratio was 0.40%. The lowest was -20.10%. And the median was -6.80%.
MEX:VRTX's 3-Year Share Buyback Ratio is ranked better than 94.87% of 1189
companies
in the Biotechnology industry
Industry Median: -11.7
vs MEX:VRTX: 0.40
Vertex Pharmaceuticals (MEX:VRTX) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Vertex Pharmaceuticals 3-Year Share Buyback Ratio Related Terms
MEX:VRTX vs REGN, RVMD, ALNY: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's 3-Year Share Buyback Ratio falls into.
Vertex Pharmaceuticals 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 0.40 mean?
Vertex Pharmaceuticals (MEX:VRTX) has a 3-Year Share Buyback Ratio of 0.40 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Vertex Pharmaceuticals and its competitors. According to the industry distribution chart, Vertex Pharmaceuticals ranks #61 out of 1189 companies in the Biotechnology industry, placing it in the top 5.1%.
Is Vertex Pharmaceuticals' 3-Year Share Buyback Ratio too high?
Vertex Pharmaceuticals' current 3-Year Share Buyback Ratio is 0.40. Based on the distribution chart, Vertex Pharmaceuticals ranks #61 out of 1189 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vertex Pharmaceuticals has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' 3-Year Share Buyback Ratio compare to REGN and RVMD?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #61 out of 1189 companies for 3-Year Share Buyback Ratio. This places Vertex Pharmaceuticals in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current 3-Year Share Buyback Ratio is 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN9,038.11, compared to a current price of MXN8,326.00 — trading 7.9% below its estimated fair value. The current 3-Year Share Buyback Ratio is 0.40. Vertex Pharmaceuticals' overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current 3-Year Share Buyback Ratio is 0.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN8,326.00 is trading 7.9% below its estimated GF Value™ of MXN9,038.11.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:VRTX:
3-Year Share Buyback Ratio: 0.40
GF Value™: MXN9,038.11 vs. price of MXN8,326.00 (7.9% below fair value)
No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
92GF Score
Get the complete analysis for MEX:VRTX
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VRTX has been successfully added to your 
